1. Acute coronary syndrome (ACS) patients requiring percutaneous coronary intervention (PCI) who received either heparin or bivalirudin were not significantly different in either the rates of major adverse cardiovascular events and overall adverse clinical events. 2. Use of bivalirudin in patients with ACS requiring PCI yielded a significantly lower rate of any-cause death as well
↧